Linked Life Data

322607

Source:http://linkedlifedata.com/resource/pubmed/id/322607

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1977-5-12
pubmed:abstractText
The pharmacological and clinical properties of bacampicillin in three dosage groups were studied in 66 hospitalized patients with unilateral acute peritonsillitis in a comparison with ampicillin. Bacampicillin is a new semisynthetic aminopenicillin which is rapidly converted to ampicillin but is better absorbed. Both drugs were given orally. The mean individual peak serum levels achieved with 200, 400, and 800 mg of bacampicillin in the first morning dose were 4.9, 6.8, and 11.9 mg/liter, respectively, with an almost linear dose response. The peak level of 800 mg of bacampicillin was significantly higher than the 6.8 mg/liter noted after a nearly equimolar dose of 500 mg of ampicillin. A linear relationship was also seen between dose and area under the serum concentration-time curve. Preliminary antibiotic concentration studies in five patients indicated therapeutic levels in peritonsillar pus. Beta-streptococci alone or in combination with anaerobes were isolated from about half of the abscesses, whereas anaerobes were isolated from the other half. Treatment was supplemented by surgical procedures in the majority of cases. The clinical effect was good in all treatment groups, with only one relapse. All beta-streptococci were eliminated during therapy. The total number of gastrointestinal side effects was significantly lower in patients treated with bacampicillin, although the difference in frequency of diarrhea alone was not significant.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/322607-1060635, http://linkedlifedata.com/resource/pubmed/commentcorrection/322607-1103921, http://linkedlifedata.com/resource/pubmed/commentcorrection/322607-1211909, http://linkedlifedata.com/resource/pubmed/commentcorrection/322607-15825424, http://linkedlifedata.com/resource/pubmed/commentcorrection/322607-4570273, http://linkedlifedata.com/resource/pubmed/commentcorrection/322607-4584904, http://linkedlifedata.com/resource/pubmed/commentcorrection/322607-4597253, http://linkedlifedata.com/resource/pubmed/commentcorrection/322607-5452419, http://linkedlifedata.com/resource/pubmed/commentcorrection/322607-6181, http://linkedlifedata.com/resource/pubmed/commentcorrection/322607-788140, http://linkedlifedata.com/resource/pubmed/commentcorrection/322607-789324
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
185-90
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1977
pubmed:articleTitle
Pharmacological and clinical study of bacampicillin in acute peritonsillitis--a comparison with ampicillin.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial